Compare Cadila Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs VENUS REMEDIES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE VENUS REMEDIES CADILA HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x 29.7 -13.7 - View Chart
P/BV x 5.2 0.9 566.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CADILA HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
VENUS REMEDIES
Mar-18
CADILA HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs352126 279.8%   
Low Rs20761 338.0%   
Sales per share (Unadj.) Rs139.2301.8 46.1%  
Earnings per share (Unadj.) Rs11.8-24.9 -47.3%  
Cash flow per share (Unadj.) Rs18.62.5 729.7%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs101.4293.3 34.6%  
Shares outstanding (eoy) m1,023.7412.34 8,296.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.00.3 647.7%   
Avg P/E ratio x23.7-3.8 -631.7%  
P/CF ratio (eoy) x15.036.7 41.0%  
Price / Book Value ratio x2.80.3 864.7%  
Dividend payout %29.80-   
Avg Mkt Cap Rs m286,0331,154 24,790.7%   
No. of employees `00013.40.9 1,449.2%   
Total wages/salary Rs m24,145393 6,142.2%   
Avg. sales/employee Rs Th10,632.74,026.1 264.1%   
Avg. wages/employee Rs Th1,801.2425.0 423.8%   
Avg. net profit/employee Rs Th898.5-331.8 -270.8%   
INCOME DATA
Net Sales Rs m142,5313,724 3,827.3%  
Other income Rs m1,13923 5,062.2%   
Total revenues Rs m143,6703,747 3,834.7%   
Gross profit Rs m24,198395 6,129.2%  
Depreciation Rs m6,965338 2,058.8%   
Interest Rs m3,418354 964.7%   
Profit before tax Rs m14,954-275 -5,431.9%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,19832 10,120.3%   
Profit after tax Rs m12,044-307 -3,924.4%  
Gross profit margin %17.010.6 160.1%  
Effective tax rate %21.4-11.5 -186.3%   
Net profit margin %8.5-8.2 -102.5%  
BALANCE SHEET DATA
Current assets Rs m87,1542,638 3,304.2%   
Current liabilities Rs m82,6942,305 3,588.1%   
Net working cap to sales %3.18.9 35.0%  
Current ratio x1.11.1 92.1%  
Inventory Days Days71135 52.7%  
Debtors Days Days9446 202.5%  
Net fixed assets Rs m133,2364,871 2,735.4%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m102,7333,496 2,938.9%   
Net worth Rs m103,7573,619 2,866.9%   
Long term debt Rs m32,1461,374 2,338.9%   
Total assets Rs m236,8667,509 3,154.6%  
Interest coverage x5.40.2 2,410.6%   
Debt to equity ratio x0.30.4 81.6%  
Sales to assets ratio x0.60.5 121.3%   
Return on assets %6.50.6 1,034.0%  
Return on equity %11.6-8.5 -136.9%  
Return on capital %13.71.6 867.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m52,7520-   
Fx outflow Rs m14,504517 2,808.1%   
Net fx Rs m38,248-517 -7,405.2%   
CASH FLOW
From Operations Rs m25,054514 4,870.5%  
From Investments Rs m-10,123-123 8,223.4%  
From Financial Activity Rs m-10,942-387 2,826.7%  
Net Cashflow Rs m3,9894 94,976.2%  

Share Holding

Indian Promoters % 74.8 32.9 227.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,611.1%  
FIIs % 5.9 0.6 1,017.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 66.4 16.6%  
Shareholders   44,069 20,121 219.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  IPCA LABS  JUBILANT PHARMOVA   NEULAND LABS  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Apr 16, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS